[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acute-exacerbation-of-chronic-obstructive-pulmonary-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acute-exacerbation-of-chronic-obstructive-pulmonary-disease":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,43,71,98,135,160,187,212,237,257],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100649483","prevalence-and-clinical-outcome-of-eosinophilic-copd-100649483",false,"NCT07734883","Prevalence and Clinical Outcome of Eosinophilic COPD","Prevalence and Clinical Outcome of Eosinophilic COPD at Assiut University","Inclusion Criteria:\n\n* Patients aged \\> 40 years.\n* Confirmed diagnosis of COPD according to GOLD 2026 guidelines.\n* Presented with acute exacerbation of COPD (AECOPD) characterized by the onset or worsening of at least two symptoms (cough, phlegm, purulent sputum, wheezing, or dyspnea) persisting for a minimum of 48 hours, excluding other potential causes, such as left or right cardiac dysfunction, pulmonary embolism, pneumothorax, pleural effusion, arrhythmia and other related diseases.\n\nExclusion Criteria:\n\n* Patients with asthma or asthma-COPD overlap.\n* Patients who need ICU admission.\n* Patients receiving systemic corticosteroids within the previous 4 weeks.\n* Hematological disorders affecting eosinophil count.\n* Active pulmonary tuberculosis.\n* Parasitic infections confirmed by stool analysis.","ALL","40 Years",{"count":19,"type":20},70,"ESTIMATED","OBSERVATIONAL","Chronic Obstructive Pulmonary Disease (COPD) is a lung condition characterized by chronic breathing symptoms and progressive airflow blockages. A specific type of COPD, known as eosinophilic COPD, involves higher levels of white blood cells called eosinophils and is known to influence disease outcomes and treatment responses. Currently, there is limited data regarding the prevalence and clinical outcomes of eosinophilic COPD in Upper Egypt, particularly among patients at Assiut University Hospitals.\n\nThe main objective of this prospective observational study is to determine how common eosinophilic COPD is among patients experiencing an acute worsening of their COPD symptoms (an exacerbation) at Assiut University Hospitals. The study also aims to evaluate the clinical outcomes associated with this specific phenotype.\n\nResearchers will observe patients over the age of 40 with a confirmed COPD diagnosis who are admitted to the hospital for an acute exacerbation. As part of their standard hospital care, participants will undergo routine clinical assessments, including a review of their medical history, physical examinations, lung function tests (spirometry), and standard blood tests to measure their blood eosinophil count.\n\nThe study will compare patients with eosinophilic COPD to those with non-eosinophilic COPD. Researchers will specifically evaluate differences in the severity of the exacerbation, the duration of the hospital stay, and the need for ventilator support. The findings aim to contribute to better, more personalized treatment strategies and improved clinical outcomes for COPD patients in the region.",[24,25,26],"Chronic Obstructive Pulmonary Disease (COPD)","Eosinophilic COPD","Acute Exacerbation of Chronic Obstructive Pulmonary Disease",[25,28,29,30],"COPD Exacerbation","Blood Eosinophils","Sputum Eosinophilia","NOT_YET_RECRUITING","2026-07-25",{"date":34,"type":35},"2026-07-29","ACTUAL",{"date":37,"type":20},"2026-08",{"date":39,"type":20},"2027-09",{"name":41,"class":42},"Assiut University","OTHER",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":50,"enrollmentInfo":51,"targetDuration":53,"studyType":21,"phases":4,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":70},"100648215","interoception-and-symptom-perception-in-acute-copd-exacerbation-100648215","NCT07719231","Interoception and Symptom Perception in Acute COPD Exacerbation","Investigation of the Relationship Between Interoception, Disease Severity, Perception of Dyspnea, Depression, and Sleep Quality in Hospitalized Patients With Acute COPD Exacerbation","Inclusion Criteria:\n\n* Physician-confirmed diagnosis of acute exacerbation of COPD with hospitalization\n* Age 40 years or older\n* Conscious and able to communicate\n* Willing to participate and provide written informed consent\n\nExclusion Criteria:\n\n* Presence of delirium or severe cognitive impairment\n* Requirement for invasive mechanical ventilation\n* Clinical instability preventing safe administration of assessment tools\n* History of severe neurological or psychiatric disorders\n* Any history of malignancy\n* Presence of pneumonia\n* History of stroke","75 Years",{"count":52,"type":20},50,"1 Day","Interoception refers to the process of perceiving and interpreting internal physiological signals and plays a central role in symptom perception. In conditions with a high symptom burden such as chronic obstructive pulmonary disease (COPD), clinical features including dyspnea perception, depression, and sleep quality may be influenced not only by disease severity but also by the interpretation of internal bodily signals.\n\nRecent evidence suggests that respiratory-related internal signals are transmitted to the central nervous system through multiple afferent pathways and integrated within cortical and subcortical networks, contributing to subjective experiences such as dyspnea. In this context, dyspnea perception may arise from the interaction between disease severity and interoceptive processes.\n\nDepressive symptoms and impaired sleep quality are also closely associated with interoceptive processes and may contribute to the perception of respiratory symptoms. However, studies simultaneously examining interoception, disease severity, dyspnea perception, depression, and sleep quality in hospitalized patients with acute COPD exacerbation are limited.\n\nThis prospective, observational, cross-sectional study will include 50 individuals aged 40 years and older who are hospitalized with acute COPD exacerbation in a Chest Diseases clinic. Data will be collected at a single time point when patients are clinically stable, without interfering with routine clinical care. Participants will be recruited using a consecutive sampling method.\n\nSociodemographic and clinical data will be obtained from patient records and a structured data collection form. Disease severity will be assessed using oxygen requirement, respiratory rate, oxygen saturation, and arterial blood gas values when available. Interoception will be evaluated using the Multidimensional Assessment of Interoceptive Awareness (MAIA-2). Symptom burden will be assessed with the COPD Assessment Test (CAT), dyspnea with the Modified Medical Research Council (mMRC) scale, sleep quality with the Richards-Campbell Sleep Questionnaire (RCSQ), and depressive symptoms with the Hospital Anxiety and Depression Scale - Depression subscale (HADS-D).\n\nStatistical analyses will be performed using IBM SPSS Statistics software. Relationships between variables will be analyzed using Pearson or Spearman correlation depending on data distribution, with a significance level of p\\\u003C0.05.",[26,56],"Interoceptive Awareness",[58,56,59,60],"Acute Exacerbation of COPD","Dyspnea Perception","Sleep Quality","2026-07-17",{"date":63,"type":35},"2026-07-22",{"date":65,"type":20},"2026-07-20",{"date":67,"type":20},"2026-08-25",{"name":69,"class":42},"Saglik Bilimleri Universitesi",1,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":78,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":96,"leadSponsor":97,"locationsCount":4},"100646422","red-blood-cell-and-platelet-indices-for-predicting-outcomes-in-acute-exacerbations-of-copd-100646422","NCT07693127","Red Blood Cell and Platelet Indices for Predicting Outcomes in Acute Exacerbations of COPD","Assessment of Red Blood Cell and Platelet Indices in Predicting Outcome in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease","Inclusion Criteria:\n\n* Patients above 18 years admitted to the department with AECOPD defined as an event characterized by increased dyspnea and\u002For cough and sputum that worsens in ≤14 days.\n\nExclusion Criteria:\n\n* Primary reason for admission other than AECOPD.\n* The patient has a diagnosis of connective tissue disorder, inflammatory bowel disease, or hematological system diseases (such as malignancy, thalassemia, hemolytic anemia).","18 Years",{"count":52,"type":20},"The purpose of this study is to evaluate if standard, easily accessible blood tests can help doctors predict the severity and outcomes of sudden flare-ups in patients with Chronic Obstructive Pulmonary Disease (COPD).\n\nWhen a patient's COPD suddenly worsens, an event called an acute exacerbation, it can lead to serious health complications, breathing difficulties, and hospitalization. Currently, doctors need simple and cost-effective ways to figure out early on which patients are at the highest risk for severe complications.\n\nThis observational study will focus on specific components of a routine Complete Blood Count (CBC) test. Researchers will look at the size, volume, and variation of red blood cells (such as Red Cell Distribution Width, or RDW) and platelets. Both red blood cells and platelets are known to be affected by the body's systemic inflammatory response during a severe COPD flare-up.\n\nParticipants will include adults over 18 years old who are admitted to the hospital for an acute exacerbation of COPD. As part of the study, researchers will collect and analyze routine clinical data, including:\n\n* Medical history and physical examination findings (including dyspnea severity).\n* Standard laboratory blood tests (evaluating red blood cells, platelets, kidney and liver function, and inflammation markers).\n* Arterial blood gas levels.\n* Pulmonary function tests (breathing tests to measure lung capacity).\n* High-resolution computed tomography (HRCT) chest scans.\n\nBy analyzing this information, the study aims to determine if red blood cell and platelet indices can accurately predict important clinical outcomes. These outcomes include the need for Intensive Care Unit (ICU) admission, the need for a mechanical ventilator (breathing machine), the total length of the hospital stay, and in-hospital mortality. Identifying reliable biomarkers could help healthcare providers make faster, more targeted treatment decisions for COPD patients.",[26,24,82],"AECOPD",[84,85,86,87,88,89,90,91],"Red Blood Cell Indices","Platelet Indices","Red Cell Distribution Width (RDW)","Mean Platelet Volume (MPV)","Platelet Distribution Width (PDW)","Biomarkers","Prognosis","Systemic Inflammation","2026-07-03",{"date":94,"type":35},"2026-07-09",{"date":37,"type":20},{"date":39,"type":20},{"name":41,"class":42},{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":16,"minAge":78,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":109,"phases":110,"briefSummary":112,"conditions":113,"keywords":116,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":134},"100524894","nasal-high-flow-versus-non-invasive-ventilation-for-early-treatment-of-acute-exacerbation-of-chronic-obstructive-pulmonary-disease-with-hypercapnic-acidosis-100524894","NCT06114667","Nasal High Flow Versus Non-invasive Ventilation for Early Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease With Hypercapnic Acidosis","Nasal High Flow in Early Management of Patients Admitted to the Emergency Department for Acute Exacerbation of Chronic Obstructive Pulmonary Disease With Hypercapnic Acidosis : a Randomized Controlled Non Inferiority Study","HiCOPD","Adult Patient admitted to the ED for acute exacerbation of COPD (AE-COPD)and respiratory acidosis (PaCO2 \\> 45 mmHg and pH \\\u003C7.35), for whom ventilatory assistance by NIV is indicated (SPLF 2017, GOLD2023 recommendations)\n\nInclusion Criteria:\n\n* Patients with ability to understand and give an informed consent\n* Patients affiliated with or who benefit from a social security\n* Patients admitted to the emergency department for a clinical suspicion of AE-COPD based on clinical history, physical examination and chest X-ray (SPLF 2017)\n* Patients with acute respiratory failure defined by: Respiratory rate ≥ 25 bpm AND\u002FOR Signs of respiratory failure (use of accessory respiratory muscles, paradoxical abdominal movement)\n* Patients with respiratory acidosis defined by PaCO2 \\> 45 mmHg AND pH \\\u003C 7.35 (measured on arterial blood gas)\n\nExclusion Criteria:\n\n* Patients who have already received NIV treatment before inclusion (including in-hospital or prehospital, with the exception of NIV at home)\n* Contraindication to non-invasive ventilation (SPLF 2017 and GOLD 2023 recommendations)\n* Patient uncooperative, agitated, opponent of the technique","85 Years",{"count":108,"type":20},174,"INTERVENTIONAL",[111],"NA","The purpose of this study is to determine whether nasal high flow is non inferior to non invasive ventilation (NIV) in the early treatment of patients with acute exacerbation of chronic obstructive pulmonary disease (AE-COPD) and hypercapnic acidosis in the emergency department (ED). After obtaining informed consent, participants will be randomly assigned to receive either nasal high flow or non invasive ventilation (NIV, reference treatment) as respiratory support. Researchers will compare both respiratory support groups to see if their blood gas analysis and respiration return to normal ranges.",[26,114,115],"Hypercapnic Acidosis","Respiratory Failure With Hypercapnia",[117,118,119,120,121,122,123],"respiratory insufficiency","Hypercapnic Acute Respiratory Failure","chronic obstructive pulmonary disease exacerbation","nasal high flow","non invasive ventilation","emergency department","critical are","RECRUITING","2026-06-17",{"date":127,"type":35},"2026-06-22",{"date":129,"type":35},"2026-06-16",{"date":131,"type":20},"2028-11-01",{"name":133,"class":42},"University Hospital, Montpellier",3,{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":142,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":144,"conditions":145,"keywords":146,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":70},"100632073","decision-making-and-optimization-of-ventilatory-support-for-aecopd-patients-100632073","NCT07508943","Decision-making and Optimization of Ventilatory Support for AECOPD Patients","OPTIVENT-COPD","Inclusion Criteria:\n\n* Hospitalized patients with a documented diagnosis of acute exacerbation of chronic obstructive pulmonary disease.\n* Patients identified retrospectively from hospital records during the predefined study period.\n* Patients who received at least one form of respiratory support during the index hospitalization, including conventional oxygen therapy, high-flow nasal cannula oxygen therapy, noninvasive ventilation, or invasive mechanical ventilation.\n* Patients with available clinical records containing sufficient dynamic physiological, laboratory, and treatment-related data for retrospective analysis.\n\nExclusion Criteria:\n\n• Patients whose hospitalization was not primarily due to acute exacerbation of COPD, even if COPD was documented as a comorbidity.\n\nPatients with stable COPD and no evidence of acute exacerbation during the index hospitalization.\n\n* Patients admitted primarily for other acute conditions, including but not limited to pneumonia without documented AECOPD, acute heart failure, pulmonary embolism, pneumothorax, asthma exacerbation, trauma, or postoperative care.\n* Patients with insufficient documentation to confirm AECOPD as the primary reason for admission.\n* Patients with incomplete clinical records preventing retrospective analysis.\n* Repeated hospitalizations of the same patient during the study period, with only the first eligible admission included.",{"count":143,"type":20},1000,"The goal of this retrospective observational study is to learn about how respiratory support is selected and adjusted in hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). The main questions it aims to answer are:\n\n1. How are different respiratory support modalities selected for patients with AECOPD in real-world practice?\n2. What clinical patterns are associated with escalation, de-escalation, switching, or discontinuation of respiratory support during hospitalization? Researchers will review de-identified hospital records of patients admitted with AECOPD and analyze the dynamic use of respiratory support during hospitalization, including conventional oxygen therapy, high-flow nasal cannula oxygen therapy, non-invasive ventilation, and invasive mechanical ventilation.\n\nParticipants will not receive any study-assigned intervention. The study will use existing clinical data collected during routine inpatient care and will not change diagnosis, treatment, or follow-up.",[26],[26,147,148,149,150],"Decision-Making","Real-World Data","Dynamic Programming","Respiratory Support","2026-03-27",{"date":153,"type":35},"2026-04-02",{"date":155,"type":20},"2026-03-18",{"date":157,"type":20},"2029-03-18",{"name":159,"class":42},"Sir Run Run Shaw Hospital",{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":16,"minAge":167,"maxAge":4,"enrollmentInfo":168,"targetDuration":170,"studyType":21,"phases":4,"briefSummary":171,"conditions":172,"keywords":175,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":70},"100623211","effectiveness-of-xuanfei-jiangzhuo-decoction-for-influenza-induced-aecopd-100623211","NCT07393685","Effectiveness of Xuanfei Jiangzhuo Decoction for Influenza-Induced AECOPD","Effect of Xuanfei Jiangzhuo Decoction on Clinical Remission in Influenza-Induced AECOPD: Study Protocol for a Prospective, Real-World Cohort Study","Inclusion Criteria:\n\n* Diagnosed with Influenza-induced AECOPD according to the Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (GOLD 2025) and the Expert Consensus on the Diagnosis and Treatment of AECOPD in China (Updated 2023), confirmed by spirometry and viral testing (antigen or PCR), and excluding pneumonia and heart failure via chest CT and NT-proBNP.\n* Aged 60 years or older.\n* Voluntarily participate and provide written informed consent..\n\nExclusion Criteria:\n\n* Known allergy or hypersensitivity to any component of the study medications.\n* Presence of severe bacterial co-infection at enrollment requiring systemic antibiotic therapy.\n* Severe dysfunction of major organs that may interfere with efficacy or safety assessment (e.g., severe cardiac insufficiency, hepatic impairment, or renal failure).\n* Participation in other interventional clinical trials within the past 3 months.\n* Inability to be contacted for follow-up (e.g., lack of permanent address or valid contact information).\n* Any other condition that, in the opinion of the investigator, would make the patient unsuitable for study participation (e.g., severe cognitive impairment or psychiatric disorders).","60 Years",{"count":169,"type":20},300,"28 Days","The goal of this observational study is to learn if a traditional Chinese herbal medicine (Xuanfei Jiangzhuo Decoction) works to help older adults recover from a COPD flare-up caused by the flu (influenza virus). The main questions it aims to answer are:\n\nDoes the herbal medicine help participants feel better and recover faster? Does it lower the chance of getting a second infection from bacteria? Is the herbal medicine safe to use? Researchers will compare participants who choose to take the herbal medicine along with their standard flu treatment (Oseltamivir or Baloxavir) to participants who only take the standard flu treatment (Oseltamivir or Baloxavir).\n\nParticipants will:\n\nTake the herbal medicine (a liquid drink) twice a day for 5 days, or just take their standard flu medicine for 5 days.\n\nVisit the clinic 4 times over 28 days for checkups and tests. Provide blood and stool samples to help researchers understand how the medicine affects the body and gut health.\n\nAnswer simple questions about their cough, breathing, and energy levels.",[26,173,174],"Influenza, Human","Virus Diseases",[28,176,177],"Real-World Study","Traditional Chinese Medicine","2026-03-09",{"date":180,"type":35},"2026-03-12",{"date":182,"type":20},"2026-08-01",{"date":184,"type":20},"2028-05-31",{"name":186,"class":42},"Tianjin Medical University",{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":4,"eligibilityCriteria":193,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":194,"targetDuration":53,"studyType":21,"phases":4,"briefSummary":196,"conditions":197,"keywords":198,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":70},"100586667","the-severity-assessment-model-for-aecopd-with-combination-of-disease-and-syndrome-100586667","NCT06918353","The Severity Assessment Model for AECOPD With Combination of Disease and Syndrome","Construction and Evaluation of the Severity Assessment Model for AECOPD With Combination of Disease and Syndrome Based on Machine Learning","Inclusion Criteria:\n\n* Meets AECOPD diagnostic criteria.\n* Voluntarily participate in the research and sign the consent form\n\nExclusion Criteria:\n\n* Individuals with severe mental disorders and cognitive impairments who are unable to communicate normally",{"count":195,"type":20},1500,"The establishment of the AECOPD severity assessment model can quickly and accurately evaluate the condition, which is of great significance for standardizing diagnosis and treatment, improving efficacy, and improving prognosis. At the same time, it can provide ideas and methods for the research of disease assessment models in related fields.",[26],[26,199,200,201,202],"Severity Assessment Model","Combination of Disease and Syndrome","Classification and Regression Trees","Artificial Neural Network","2025-04-09",{"date":205,"type":35},"2025-04-11",{"date":207,"type":20},"2025-04-01",{"date":209,"type":20},"2028-12-31",{"name":211,"class":42},"Henan University of Traditional Chinese Medicine",{"id":213,"slug":214,"hasResults":11,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":218,"eligibilityCriteria":219,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":220,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":222,"conditions":223,"keywords":224,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":4},"100574098","study-to-evaluate-the-clinical-value-and-safety-of-xiyanping-injection-in-the-treatment-of-acute-exacerbation-of-chronic-obstructive-pulmonary-diseasecopd-based-on-real-world-clinical-data-100574098","NCT06754865","Study to Evaluate the Clinical Value and Safety of Xiyanping Injection in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease(COPD) Based on Real-world Clinical Data","A Muulticenter, Open, Non-interventional, Retrospective Cohort Study to Evaluate the Clinical Value and Safety of Xiyanping Injection in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease(COPD) Based on Real-world Clinical Data","XYP-202401","Inclusion Criteria:\n\n1. Discharged with chronic obstructive pulmonary disease;\n2. Hospitalized patients with COPD or AECOPD combined with lower respiratory tract infection;\n3. The treatment course of Xiyanping injection in the exposed group was ≥3 days, and the non-exposed group did not use Xiyanping injection;\n4. Study patients with complete medical records.\n\nExclusion Criteria:\n\n1. Researchers believe that multiple proprietary Chinese medicines with the same or similar functions (such as Tanreqing injection, Reduning injection, Yanhuning injection, etc.) have been used at the same time during treatment, resulting in no assessment of efficacy or safety;\n2. Patients with viral pneumonia or other systemic infection (such as urinary tract infection);\n3. Patients who do not use intravenous antibiotics;\n4. Refuse the case to be used by researchers.",{"count":221,"type":20},1140,"The primary objective is to evaluate the effect of Xiyanping injection on the treatment course of intravenous antibiotics for acute exacerbation of chronic obstructive pulmonary disease based on real-world clinical data, and to provide guidance and basis for the clinical application of Xiyanping injection combined with antibiotics in the treatment of acute exacerbation of chronic obstructive pulmonary disease.The secondary objectives is to evaluate the effect of Xiyanping injection on the indicators of acute exacerbation of inflammation and symptom improvement of chronic obstructive pulmonary disease.",[26],[225,226],"Acute exacerbation of chronic obstructive pulmonary disease","Xiyanping injection","2024-12-23",{"date":229,"type":35},"2025-01-01",{"date":231,"type":20},"2024-12",{"date":233,"type":20},"2025-11",{"name":235,"class":236},"Jiangxi Qingfeng Pharmaceutical Co. Ltd.","INDUSTRY",{"id":238,"slug":239,"hasResults":11,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":4,"eligibilityCriteria":243,"healthyVolunteers":11,"sex":16,"minAge":78,"maxAge":4,"enrollmentInfo":244,"targetDuration":4,"studyType":109,"phases":246,"briefSummary":247,"conditions":248,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":253,"leadSponsor":255,"locationsCount":70},"100569267","impact-of-hi-nppv-vs-li-nppv-on-tolerance-among-aecopd-patients-100569267","NCT06692023","Impact of HI-NPPV Vs LI-NPPV on Tolerance Among AECOPD Patients","Impact of High-Intensity-NIV Vs Low-intensity-NIV on Subjective Tolerance Amomg Patients with AECOPD : a Randomised Cross-over Pilot Study","Inclusion Criteria:\n\n* AECOPD confirmed by the 2019 criteria of the Global Initiative for Chronic Obstructive Lung Disease (GOLD);\n* Arterial pH \\\u003C7.35 and PaCO2 \\>45 mmHg at screening entry;\n* PaCO2 \\>45 mmHg after a 6-hour trial of low-intensity NPPV.\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* Excessive respiratory secretions with weak cough\n* Upper airway obstruction\n* Recent oral, facial, or cranial trauma or surgery\n* Recent gastric or esophageal surgery\n* Presence of restrictive ventilatory dysfunction (eg, consolidation or removal of at least one pulmonary lobe, massive pleural effusion, chest wall deformity, continuous strapping with thoracic or abdominal bandage, or severe abdominal distension)\n* Active upper gastrointestinal bleeding\n* Cardiac or respiratory arrest\n* Arterial oxygen tension\u002Ffraction of inspired oxygen (PaO2\u002FFiO2) \\\u003C100 mmHg\n* Pneumothorax\n* Obvious emphysematous bullae confirmed by chest CT scan\n* Ventricular arrhythmia or myocardial ischemia\n* Severe hemodynamic instability (mean arterial pressure \\\u003C65 mmHg)\n* Severe metabolic acidosis (pH \\\u003C7.20 and bicarbonate \\\u003C22 mmol\u002FL)\n* Refusal to receive NPPV or give informed consent\n* Prior endotracheal intubation or tracheostomy during the current hospitalization\n* A do-not-intubate order",{"count":245,"type":20},20,[111],"To determine whether high-intensity NPPV, compared with low-intensity NPPV, could have an effect on the subjective tolerance in patients with an AECOPD and hypercapnia.",[26],"2024-11-14",{"date":251,"type":35},"2024-11-18",{"date":231,"type":20},{"date":254,"type":20},"2025-10",{"name":256,"class":42},"Beijing Chao Yang Hospital",{"id":258,"slug":259,"hasResults":11,"nctId":260,"briefTitle":261,"officialTitle":262,"acronym":4,"eligibilityCriteria":263,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":264,"enrollmentInfo":265,"targetDuration":4,"studyType":109,"phases":267,"briefSummary":268,"conditions":269,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":4},"100551098","effects-of-chinese-medicine-on-patients-with-severe-acute-exacerbation-of-copd-100551098","NCT06455670","Effects of Chinese Medicine on Patients With Severe Acute Exacerbation of COPD","Effects of Chinese Medicine on Patients With Severe Acute Exacerbation of COPD：A Multicentre, Randomised, Double-blind, Placebo-parallel Controlled Trial","Inclusion Criteria:\n\n1. Patients with severe AECOPD.;\n2. Age 40-80 years old;\n3. Chinese medicine diagnosis consistent with external cold and internal drink syndrome, or phlegm-heat congestion of the lungs syndrome, or phlegm turbidity obstruction of the lungs syndrome;\n4. Voluntarily accept the treatment and sign the informed consent form;\n\nExclusion Criteria:\n\n1. Pregnant and lactating women.\n2. delirious, dementia, various mental patients and other people who cannot communicate normally.\n3. Patients with severe cardiac insufficiency (NYHA grade IV), malignant arrhythmia and hemodynamic instability.\n4. Patients with acute respiratory failure who require tracheal intubation or invasive mechanical ventilation.\n5. Complicated with bronchiectasis, active tuberculosis, severe liver and kidney disease (severe liver disease refers to cirrhosis, portal hypertension and varicose vein bleeding, etc., serious kidney disease including dialysis, kidney transplantation, etc.), pneumonia, HIV infection or immunosuppressive state, advanced malignant tumor, etc.\n6. long-term bedridden patients for various reasons.\n7. Out-of-hospital treatment for more than 3 days.\n8. Participate in other drug clinical investigators within 1 month before enrollment.\n9. Allergic to therapeutic drugs.","80 Years",{"count":266,"type":20},468,[111],"The purpose of this study was to evaluate the effects of Chinese Medicine on patients with severe AECOPD, and to provide a basis for the establishment of integrated CM and Western medicine diagnosis and treatment scheme for patients with severe AECOPD.",[270],"Acute Exacerbation Of Chronic Obstructive Pulmonary Disease","2024-10-18",{"date":273,"type":35},"2024-10-22",{"date":275,"type":20},"2024-10-20",{"date":277,"type":20},"2027-10-31",{"name":211,"class":42}]